Opinion
Video
Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
- How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?
